Case Reports
Vol. 65 No. 3 (2013)
https://doi.org/10.4081/reumatismo.2013.134

Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 4 March 2013
Accepted: 17 June 2013
Published: 24 July 2013
2960
Views
928
Downloads
Certolizumab pegol, Axial spondyloarthritis, Magnetic resonance.
Rheumatology

Authors

A. Spadaro
a.spadaro.reuma@virgilio.it
Dipartimento di Medicina Interna e Specialità Mediche, U.O.C. di Reumatologia, Università “La Sapienza”, Roma, Italy.
A. Scarno
Dipartimento di Medicina Interna e Specialità Mediche, U.O.C. di Reumatologia, Università “La Sapienza”, Roma, Italy.
A. Carboni
Dipartimento di Medicina Interna e Specialità Mediche, U.O.C. di Reumatologia, Università “La Sapienza”, Roma, Italy.
F.M. Perrotta
Dipartimento di Medicina Interna e Specialità Mediche, U.O.C. di Reumatologia, Università “La Sapienza”, Roma, Italy.
C. Catalano
Dipartimento di Medicina Molecolare, Radiologia Centrale U.O.C. A, Università “La Sapienza”, Roma, Italy.
E. Lubrano
Dipartimento di Medicina e di Scienze per la Salute, Università del Molise, Campobasso, Italy.
G. Valesini
Dipartimento di Medicina Interna e Specialità Mediche, U.O.C. di Reumatologia, Università “La Sapienza”, Roma, Italy.
In axial spondyloarthritis (SpA), the efficacy of certolizumab pegol (CZP), a novel pegylated anti-tumor necrosis factor alpha drug has not been investigated. We report that CZP showed a rapid effectiveness, assessed clinically and by magnetic resonance imaging, in a patient with a non-radiographic axial SpA, classified according to Assessment in SpondyloArthritis International Society (ASAS) criteria. This case suggests that CZP could be considered an useful treatment in non-radiographic axial SpA, supporting that an earlier therapeutic approach could play a relevant role in the management of the disease.

Downloads

Download data is not yet available.
A. Spadaro, Dipartimento di Medicina Interna e Specialità Mediche, U.O.C. di Reumatologia, Università “La Sapienza”, Roma

How to Cite



1.
Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis. Reumatismo [Internet]. 2013 Jul. 24 [cited 2026 Oct. 18];65(3):134-7. Available from: https://www.reumatismo.org/reuma/article/view/reumatismo.2013.134

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.